PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Curr HIV Res. Author manuscript; available in PMC Aug 15, 2013.
Published in final edited form as:
PMCID: PMC3744389
NIHMSID: NIHMS498042
Mucosal Transmission of Human Immunodeficiency Virus
Denis M. Tebit,1 Nicaise Ndembi,2 Aaron Weinberg,3 and Miguel E. Quiñones-Mateu4*
1Department of Medicine, Case Western Reserve University, Cleveland, Ohio
2Institute of Human Virology, Abuja, Nigeria
3School of Medicine, School of Dental Medicine, Case Western Reserve University, Cleveland, Ohio
4Department of Pathology, Case Western Reserve University, Cleveland, Ohio
*Corresponding Author: Department of Pathology, Case Western Reserve University/University Hospitals Case Medical Center, 10900 Euclid Avenue, Cleveland, Ohio 44106-7288, Phone: (216) 368-3611. Fax: (216) 368-1539. meq/at/case.edu
Since the beginning of the AIDS pandemic, and following the discovery of the human immunodeficiency virus (HIV) as the etiological agent of the disease, it was clear that the virus gains access to the human host predominantly through the mucosal tissue after sexual exposure. As a consequence, the female genital tract (vaginal and cervical), as well as the rectal, penile, and oral mucosae have been extensively studied over the last thirty years towards a better understanding of - and to develop strategies to prevent - sexual HIV transmission. This review seeks to describe the biology of the events leading to HIV infection through the human mucosa and introduce some of the approaches attempted to prevent the sexual transmission of HIV.
HIV mucosal infection plays a critical role not only in virus transmission but also in AIDS pathogenesis, affecting mucosal surfaces of the gastrointestinal tract early on by depleting it of CD4+ T helper cells independently of the virus transmission route [1]. Although current antiretroviral therapy helps controlling HIV infection in most patients, it cannot eradicate the virus from the human host [2]. In addition, an effective HIV vaccine seems to still be difficult to achieve, at least in the near future [3]. Therefore, the development and use of HIV microbicides (i.e., topical pre-exposure prophylaxis) has become the most promising approach to prevent HIV transmission.
Most HIV infections occur as consequence of unprotect sexual contact [4], with the risk of transmission being higher during anal intercourse (0.65% to 1.7%)[5, 6] than via heterosexual intercourse (0.03% to 0.5%)[4, 6]. Interestingly, HIV transmission rate through the oral mucosa varies from 0.1% to 2% during oral sex [7, 8] and it could be as high as 5% to 20% during breastfeeding [9, 10]. Here we review the multiple host and viral factors associated with HIV mucosal infection and transmission as a preamble to the numerous approaches described in this issue as current and potential HIV microbicides.
The AIDS pandemic has arisen largely through heterosexual transmission of HIV, yet the probability of infection for each encounter with the virus is quite small, i.e., less than 0.0014 based in studies of discordant couples [11-14]. This poor efficiency in viral transmission may be the consequence of low amounts of virus inoculum, restricted access to target cells, selective transmission, and/or outgrowth of a subset of viral variants within the population. There is clear evidence from cross-sectional studies of individuals with acute and early infections that transmission is associated with a population bottleneck [15-19]. Early studies of mother to infant HIV transmission first demonstrated that a restricted subset of viruses is present soon after infection [20, 21]. In these limited lineages harmful mutations accumulate over time causing the average fitness of the virus population to decline, a process commonly associated with Muller's ratchet [22-26]. A detailed molecular understanding of the transmission and the early evolution of HIV, including a precise description of the transmitted or early founder virus, is critical in the development of not only microbicides but a potential HIV vaccine [18].
Early Events Leading to Productive HIV Infection
HIV gains entry into the body mainly during sexual intercourse by crossing epithelial barriers covering the mucosal surfaces of the female and male (penis) genital tracks as well as the anal/rectal epithelia. In the female genital tract virus transmission involves early capture by epidermal Langerhans cells (LCs) in the vagina and endocervix stratified epithelia, a process facilitated by their close proximity to the mucosal surface. Langerhans cells bind the envelope gp120 of HIV through their C-type unique langerin, a process that at low viral loads might lead to the degradation of HIV [27, 28]. On the contrary, if the protective effect of langerin is inhibited due to higher viral concentrations, the internalized virus will be transferred to T-cells leading to a productive infection of these cells within the mucosae or in draining lymph nodes following migration of LCs to secondary lymphoid organs [29-31].
As described above, within hours of infection, HIV crosses the mucosal epithelial barrier to establish a founder population of infected cells [32, 33]. This population expands locally during the first week of infection generating a viral pool that establishes a self-propagating systemic infection in the secondary lymphoid organs [32]. As virus access to more susceptible target cells increase during the second week of infection, a significant increase in replication in the lymphatic tissues occurs. The peak of virus replication in blood and tissue happens during the second week after infection before declining to stable levels around fours weeks post exposure [34]. The infected lymphatic tissues act as reservoirs for virus production and storage as well as harboring of proviruses in latently infected cells [35]. Interestingly, although it is estimated that a single virion is effectively transmitted, HIV diversity increases over the course of infection due to the continuous replication of the virus and the error prone nature of the reverse transcriptase [36]. Such diversity results in natural selection caused partly by host immune response, which eventually facilitates viral persistence [15, 18].
Prevalence and Efficiency of Vaginal Transmission
During sexual intercourse, HIV transmission from male to female is more efficient than from female to male, thereby making women a disproportionately more susceptible population to HIV infection [37]. As consequence, 76% of young people (aged 15–24 years) living worldwide with HIV are female with vaginal intercourse remaining the most prevalent route of infection [38]. Vaginal and cervical epithelia are most likely the primary sites where HIV from male semen and cells from the female genital tract first encounter. Interestingly, although most studies on mucosal HIV transmission have focused on cell-free virions [39], all genital fluids that transmit HIV such as seminal plasma and cervicovaginal secretions also carry HIV-infected cells [40]. Seminal plasma may contain up to 105 white blood cells/mL including substantial numbers of HIV susceptible macrophages and CD4+ T-cells [40]. This is particularly important due to recent studies suggesting that HIV transcytosis across simple epithelia is more efficient if the viruses bud via viral synapses rather than infecting via cell-free fluids [41, 42]. In addition, several factors present in seminal plasma can either enhance or inhibit HIV infection of T-cells. For example, human plasma abrogates the capture and transmission of HIV to CD4+ cells mediated by DC-SIGN [43] and semen-derived amyloid fibrils drastically enhance HIV infection [44].
Innate Immunity and Protection from HIV Infection in the Vagina/Cervix
The mucosal epithelium provides a robust physical and immunological barrier that acts as the first line of defense against viral entry in the endocervix and the upper female reproductive tract. It does mediate innate defenses against microbes under hormonal control and functions by the recognition and secretion via Toll-like receptors of host-derived defensins and other antimicrobial peptides and enzymes that respond to pathogen-associated molecular patterns [45]. Chemokines and cytokines also recruit plasmacytoid dendritic cells (pDC) that mediate innate defenses and inflammation [46]. These defenses provide a series of inhibitory activities inhibiting HIV entry and replication. For example, SDF-1 blocks viral entry mediated by CXCR4 while MIP-1α/β and RANTES blocks CCR5-based entry [47]. Following vaginal inoculation, MIP-3α recruits interferon (IFN)-α/β producing pDCs to the endocervix and lead to an increase in IFN-γ expression in the vaginal tissues [48]. In non-human primates (e.g., macaques), such innate immune defenses could cumulatively lead to a limited number of infecting founder viruses despite a large dose of initial virus inoculum. Interestingly, a recent study used proteomics to identify serpin and cystatin antiproteases as host factors that could be playing a role in providing protection against HIV in the female genital tract of exposed, but uninfected, female sex workers [49]. This would explain the low probability, although still effective and probable, of HIV transmission in humans, i.e., approximately 1 in 100 or 1,000 per coital act [12, 13].
Importance of Developing Microbicides to Control HIV Vaginal Transmission (DENIS)
Most HIV microbicides tested during the last 20 years have failed to demonstrate meaningful protection against HIV infection [50]. There is no doubt that topical pre-exposure prophylaxis aimed to prevent vaginal/cervical HIV transmission would be a major step towards controlling the HIV/AIDS epidemic by allowing women self protection against HIV infection. Sub-Saharan Africa accounts for approximately 70% of the global burden of HIV and women in this region are disproportionately affected by AIDS [38], mostly because of their inability to successfully negotiate mutual monogamy or condom use. Although there is still a lot of work to do in order to develop effective microbicides to reduce HIV acquisition among women, promising data from the CAPRISA 004 trial showed that a 1% vaginal gel formulation of tenofovir reduced HIV acquisition by an estimated 39% overall and by 54% in women with high gel adherence [51]. Thus, it is possible that a combination of condom use and microbicides based on one or more antiretroviral drugs could have a considerable impact in preventing HIV transmission via the female genital tract.
Mechanisms of Rectal HIV Transmission
In addition to the vaginal/cervical epithelia, the rectal epithelium represents the predominant route of HIV transmission during sexual intercourse. Worldwide, men having sex with men (MSM) is the population group with the highest risk of acquiring HIV, including developing countries [38]. In 2009, men having sex with men (MSM) represented close to 60% of all new HIV infections in the United States and 40% in Canada [52, 53]. However, little information is known on the anal sexual practices of heterosexual individuals and its role in the spread of HIV in sub-Saharan Africa [54-56].
The relative ease by which HIV is transmitted rectally [54-56] makes this a particularly important, although relatively neglected, route to target with prevention strategies [57-59]. The gastrointestinal mucosa is a secondary lymphoid organ that contains the majority of the body's CD4+ lymphocyte population [60, 61] and, therefore, likely represents the largest reservoir of HIV and site of viral replication compared to other body compartments. Genital and rectal sub-epithelial stromal tissues are densely populated with dendritic cells, macrophages and T cells that express CD4, CCR5 and, to a lesser extent, CXCR4, all susceptible to HIV infection [14, 62]. Unlike the vagina, the rectal canal has only a single layer of columnar epithelium overlying tissue rich in activated lymphoid cells [61]. Thus, any extensive breakdown in epithelial integrity allows HIV direct access to a rich source of target cells, allowing the establishment of infection in mucosal sites [14]. A greater percentage of mucosal mononuclear cells (MMCs) than peripheral blood mononuclear cells (PBMCs) are infected by both CCR5- and CXCR4-tropic viruses [14, 63]. Passage of virus from the lumen to the cellular targets may be facilitated by binding of virus to dendritic cell projections that extend into the epithelial compartment with subsequent presentation to sub-epithelial target cells [64-66]. After initial infection, local viral replication is followed by dissemination of virus to the regional lymph nodes, at which point systemic infection is established. Studies using animal models suggest that initial infection can occur within one hour of exposure and dissemination can occur within 24 hours [64].
Development of Microbicides to Prevent Rectal HIV Transmission
As described above, the recent success of the CAPRISA 004 trial [51] indicates the potential impact of this approach on the epidemic worldwide [67]. Although these clinical findings are a breakthrough for vaginal microbicides, the differences between the microenvironments of the rectal and cervico-vaginal mucosal tissue may require that different formulations be used for the two routes [62, 66]. Several studies have demonstrated the efficacy of topical microbicides against rectal simian/human immunodeficiency virus (SHIV) transmission in macaque models [57, 58, 67]. More important, although resistance to tenofovir was not observed in people who became infected with HIV in the CAPRISA 004 trial, tenofovir is commonly used to treat HIV-infected individuals, posing a risk for the emergence and transmission of drug resistant viruses. There are currently over thirty clinically licensed antiretroviral drugs and many more in the pipeline (http://aidsinfo.nih.gov/DrugsNew/Default.aspx?MenuItem_Drugs). Ongoing [67] and future studies based on these novel anti-HIV drugs may lead to the clinical testing and usage of HIV microbicides specifically formulated for the vaginal/cervical and rectal epithelia.
As with the female genital tract and the rectal mucosae, the uncircumcised penis outer and inner foreskin is a portal of entry for HIV during sexual transmission [68, 69]. Langerhans and dendritic cells, as well as CD4+ T-cells are found in the penile foreskin [68, 70]. Uncircumcised men have a higher density and more superficial presence of Langerhans cells with reduced keratinization of the inner layer of the foreskin [68, 71]. HIV survival in the subpreputial environment increases viral entry and transmission following exposure to infected genital fluids in uncircumcised males. Moreover, retraction of the foreskin during intercourse exposes the lightly keratinized inner mucosa to vaginal/rectal secretions and to potential microtears [72]. Following male circumcision, these vulnerable tissues are removed leaving the urethral meatus as the only unkeratinized mucosa, which offers a smaller surface area for infection [73]. Therefore, circumcision has been shown to block female-to-male HIV transmission by 50% to 60% [74-76] and, consequently, is highly recommended by the WHO/UNAIDS as an HIV prevention strategy. In addition, it is possible that daily application of microbicide gels on the penis might provide protection against HIV transmission. Clinical trials will be needed to further explore the feasibility and success of this strategy compared to vaginal/cervical and rectal topical pre-exposure prophylaxis.
Although HIV transmission through the oral mucosa is a relatively rare event [77], it can occur through genital-oral or breastfeeding routes. Numerous studies have described the transmission of the virus from mothers to children during lactation [78] demonstrating that, although uncommon compared with vaginal and rectal sexual transmission, HIV infection via the oral cavity is clearly possible. The presence of virions in saliva, salivary glands, and buccal epithelial cells is well documented [79]; however, it is still controversial whether saliva is a real route of HIV transmission. On the other hand, how the innate immune and related protective properties of oral mucosal epithelium might control HIV infection during clinical exposure to infectious virus is becoming an area of intense interest. This stems from multiple studies and epidemiological reports suggesting that the oral mucosa is not as permissive for efficient HIV replication as other mucosal epithelia (e.g., vagina/cervix and anal/rectal) and, therefore, may differ in susceptibility when compared to these mucosal sites. Discovering factors that explain the differential susceptibility and resistance to HIV infection in mucosal sites will allow for the identification and development of novel protective strategies.
Potential Role of Salivary and Epithelial Innate Immune Effector Molecules during Infection with HIV
The relative infrequency of oral HIV infection can be posited to involve: (i) a thick multilayered mucosal surface as the first line of defense against microbial invasion, (ii) low salivary HIV titers, and (iii) endogenous antiviral factors present in oral secretions. Many endogenous inhibitors of HIV in saliva have been proposed (e.g., amylase, lactoferrin, proline-rich peptides, salivary mucins, thrombospondin and secretory leukocyte protease inhibitor or SLPI)[80-82]. Remarkably, these agents are also found in seminal fluid and vaginal secretions, routinely harvested from sites that are more susceptible to HIV infection [83, 84]. Furthermore, fresh human saliva cannot inactivate HIV rapidly enough to prevent entry of infectious virus into oral keratinocytes [85]. It is clear, therefore, that more information is needed to understand whether salivary innate immune factors contribute efficiently to the resistance against acquisition of HIV.
Mucosal epithelial cells also express antimicrobial peptides with antiretroviral activity. In addition to SLPI, oral epithelial cell-derived human β defensins (hBDs)[86] inhibit HIV infection of immunocompetent cells in vitro [87, 88]. When compared with adult oral mucosae, the lack of hBD and SLPI expression in fetal oral mucosae appears to render underlying immunocompetent cells more susceptible to HIV infection [89]. While transcytosis of the virions is not appreciably different in adult and fetal mucosal cells, the ease with which HIV infects the underlying lymphocytes in the fetal mucosal model, and the loss of protection by use of specific antibodies to hBDs and SLPI in the adult oral mucosae, strongly suggest that these peptides protect against HIV infection [89]. Interestingly, a notable difference between oral epithelia and most other epithelia is the constitutive expression of hBDs. These defensins are expressed only in the presence of infection or inflammation in most tissues, including skin, trachea and gut epithelium [90, 91]. However, both hBD-2 and -3 are expressed in normal uninflamed gingival tissue [92], perhaps due to chronic exposure to specific oral commensal bacteria that promote hBD expression [93]. What is less clear is whether the target cells for antiviral activity are the hBD-producing oral epithelial cells or the proximal immunocompetent cells.
Despite the myriad of studies on HIV transmission during the last thirty years, definitive information about the fate of the HIV virion in the mucosal epithelium is absent. Greater understanding of vulnerable versus less susceptible mucosal sites may help identify strategies to prevent HIV transmission. For example, it would be interesting to compare anatomic structure of different mucosal epithelia (i.e., vaginal, cervical, colorectal, intestinal, and oral) with function during HIV exposure, resting and, active HIV infection in naïve patients or treated with antiretroviral drugs. Deciphering the mechanisms underlying HIV infection through the human mucosal sites will hopefully aid in the development of novel and less invasive prophylactic strategies to prevent HIV transmission.
Acknowledgments
M.E.Q-M. was supported by research grant NIH-AI-71747. A.W. is supported by research grants NIH/NIDCR-R01-DE018276 and P01-DE019759.
1. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature. 2005 Apr 28;434(7037):1148–52. Research Support, U.S. Gov't, P.H.S. [PubMed]
2. Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? Aids. 2011 Apr 24;25(7):885–97. Editorial Research Support, Non-U.S. Gov't Review. [PubMed]
3. Girard MP, Osmanov S, Assossou OM, Kieny MP. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine. 2011 Aug 26;29(37):6191–218. [PubMed]
4. Arien K, Jespers V, Vanham G. HIV sexual transmission and microbicides. Rev Med Virol. 2011;21:110–33. [PubMed]
5. Jin F, Jansson J, Law M, Prestage GP, Zablotska I, Imrie JC, et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. Aids. 2010 Mar 27;24(6):907–13. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. [PMC free article] [PubMed]
6. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009 Feb;9(2):118–29. Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review. [PubMed]
7. Yu M, Vajdy M. Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Expert Opin Biol Ther. 2010 Aug;10(8):1181–95. Research Support, N.I.H., Extramural Review. [PMC free article] [PubMed]
8. Varghese B, Maher JE, Peterman TA, Branson BM, Steketee RW. Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis. 2002 Jan;29(1):38–43. [PubMed]
9. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA: the journal of the American Medical Association. 2000 Mar 1;283(9):1167–74. Clinical Trial Comparative Study Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S. [PubMed]
10. De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA: the journal of the American Medical Association. 2000 Mar 1;283(9):1175–82. [PubMed]
11. Piot P, Bartos M, Ghys PD, Walker N, Schwartlander B. The global impact of HIV/AIDS. Nature. 2001 Apr 19;410(6831):968–73. Review. [PubMed]
12. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. The Lancet. 2001;357(9263):1149–53. doi: 10.1016/S0140-6736(00)04331-2. S0140-6736(00)04331-2 pii. [PubMed] [Cross Ref]
13. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. The Journal of infectious diseases. 2005 May 1;191(9):1403–9. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. [PubMed]
14. Pope M, Haase AT. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med. 2003 Jul;9(7):847–52. Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review. [PubMed]
15. Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping LH, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. Journal of Virology. 2009 Apr;83(8):3556–67. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. [PMC free article] [PubMed]
16. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 2004;303(5666):2019–22. [PubMed]
17. Gottlieb GS, Heath L, Nickle DC, Wong KG, Leach SE, Jacobs B, et al. HIV-1 variation before seroconversion in men who have sex with men: analysis of acute/early HIV infection in the multicenter AIDS cohort study. The Journal of infectious diseases. 2008 Apr 1;197(7):1011–5. Multicenter Study Research Support, N.I.H., Extramural. [PMC free article] [PubMed]
18. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America. 2008 May 27;105(21):7552–7. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. [PubMed]
19. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. Journal of Virology. 2008 Apr;82(8):3952–70. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. [PMC free article] [PubMed]
20. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants [see comments] Science. 1992;255(5048):1134–7. [PubMed]
21. Zhang H, Tully DC, Hoffmann FG, He J, Kankasa C, Wood C. Restricted genetic diversity of HIV-1 subtype C envelope glycoprotein from perinatally infected Zambian infants. PLoS One. 2010;5(2):e9294. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. [PMC free article] [PubMed]
22. Novella IS, Elena SF, Moya A, Domingo E, Holland JJ. Size of genetic bottlenecks leading to virus fitness loss is determined by mean initial population fitness. JVirol. 1995;69(5):2869–72. [PMC free article] [PubMed]
23. Domingo E, Escarmis C, Sevilla N, Moya A, Elena SF, Quer J, et al. Basic concepts in RNA virus evolution. FASEB J. 1996;10(8):859–64. [PubMed]
24. Muller HJ. The relation of recombination to mutational advance. MutatRes. 1964;1:2–9. [PubMed]
25. Quinones-Mateu ME. Is HIV-1 evolving to a less virulent (pathogenic) virus? Aids. 2005 Oct 14;19(15):1689–90. Comment Editorial. [PubMed]
26. Arien KK, Vanham G, Arts EJ. Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol. 2007 Feb;5(2):141–51. [PubMed]
27. Figdor CG, van Kooyk Y, Adema GJ. C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol. 2002 Feb;2(2):77–84. Review. [PubMed]
28. de Witte L, Nabatov A, Pion M, Fluitsma D, de Jong MA, de Gruijl T, et al. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat Med. 2007 Mar;13(3):367–71. Research Support, Non-U.S. Gov't. [PubMed]
29. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol. 2008 Jun;8(6):447–57. Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review. [PMC free article] [PubMed]
30. Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity. 2007 Feb;26(2):257–70. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. [PMC free article] [PubMed]
31. Merad M, Romani N, Randolph G. Langerhans cells at the interface of medicine, science, and industry. J Invest Dermatol. 2008 Feb;128(2):251–5. Congresses. [PubMed]
32. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgrefe S, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. Journal of Virology. 2005 Jul;79(14):9217–27. Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. [PMC free article] [PubMed]
33. Zhang ZQ, Wietgrefe SW, Li Q, Shore MD, Duan L, Reilly C, et al. Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proceedings of the National Academy of Sciences of the United States of America. 2004 Apr 13;101(15):5640–5. Research Support, U.S. Gov't, P.H.S. [PubMed]
34. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature. 2010 Mar 11;464(7286):217–23. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review. [PubMed]
35. Haase AT. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol. 1999;17:625–56. Research Support, U.S. Gov't, P.H.S. Review. [PubMed]
36. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse trasncriptase. Science. 1988;242:1168–71. [PubMed]
37. Nicolosi A, Correa Leite ML, Musicco M, Arici C, Gavazzeni G, Lazzarin A. The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology. 1994;5(6):570–5. [PubMed]
38. UNAIDS. Report on the Global AIDS Epidemic. 2010
39. Bomsel M, David V. Mucosal gatekeepers: selecting HIV viruses for early infection. Nat Med. 2002 Feb;8(2):114–6. Comment News. [PubMed]
40. Anderson DJ, Politch JA, Nadolski AM, Blaskewicz CD, Pudney J, Mayer KH. Targeting Trojan Horse leukocytes for HIV prevention. Aids. 2010 Jan 16;24(2):163–87. Research Support, N.I.H., Extramural Review. [PubMed]
41. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med. 1997 Jan;3(1):42–7. Research Support, Non-U.S. Gov't. [PubMed]
42. Hubner W, Chen P, Del Portillo A, Liu Y, Gordon RE, Chen BK. Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and oligomerization monitored with live confocal imaging of a replication-competent, fluorescently tagged HIV-1. Journal of Virology. 2007 Nov;81(22):12596–607. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. [PMC free article] [PubMed]
43. Sabatte J, Ceballos A, Raiden S, Vermeulen M, Nahmod K, Maggini J, et al. Human seminal plasma abrogates the capture and transmission of human immunodeficiency virus type 1 to CD4+ T cells mediated by DC-SIGN. JVirol. 2007;81(24):13723–34. doi: 10.1128/JVI.01079-07. JVI.01079-07 pii. [PMC free article] [PubMed] [Cross Ref]
44. Munch J, Rucker E, Standker L, Adermann K, Goffinet C, Schindler M, et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell. 2007;131(6):1059–71. doi: 10.1016/j.cell.2007.10.014. S0092-8674(07)01284-6 pii. [PubMed] [Cross Ref]
45. Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L. Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev. 2005 Aug;206:306–35. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review. [PubMed]
46. Cremel M, Berlier W, Hamzeh H, Cognasse F, Lawrence P, Genin C, et al. Characterization of CCL20 secretion by human epithelial vaginal cells: involvement in Langerhans cell precursor attraction. J Leukoc Biol. 2005 Jul;78(1):158–66. Research Support, Non-U.S. Gov't. [PubMed]
47. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. AnnuRevImmunol. 1999;17:657–700. [PubMed]
48. Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. Journal of Virology. 2005 Oct;79(19):12164–72. Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. [PMC free article] [PubMed]
49. Burgener A, Rahman S, Ahmad R, Lajoie J, Ramdahin S, Mesa C, et al. Comprehensive Proteomic Study Identifies Serpin and Cystatin Antiproteases as Novel Correlates of HIV-1 Resistance in the Cervicovaginal Mucosa of Female Sex Workers. J Proteome Res. 2011 Nov 4;10(11):5139–49. [PubMed]
50. Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, et al. Whither or wither microbicides? Science. 2008 Jul 25;321(5888):532–4. [PMC free article] [PubMed]
51. Abdool KQ, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74. doi: 10.1126/science.1193748. science.1193748 pii. [PMC free article] [PubMed] [Cross Ref]
52. Prevention CfDCa. HIV Surveillance Report 2009. 2011;21 http://wwwcdcgov/hiv/topics/surveillance/resources/reports/
53. Canada PHAo. HIV and AIDS in Canada, Surveillance Report December 31, 2009. Surveillance and Risk Assessment Division, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada; 2010.
54. Veldhuijzen NJ, Ingabire C, Luchters S, Bosire W, Braunstein S, Chersich M, et al. Anal intercourse among female sex workers in East Africa is associated with other high-risk behaviours for HIV. Sex Health. 2011 Jun;8(2):251–4. Research Support, Non-U.S. Gov't. [PubMed]
55. Lane T, Pettifor A, Pascoe S, Fiamma A, Rees H. Heterosexual anal intercourse increases risk of HIV infection among young South African men. Aids. 2006 Jan 2;20(1):123–5. [PubMed]
56. Kalichman SC, Simbayi LC, Cain D, Jooste S. Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa. Sex Transm Infect. 2009 Oct;85(6):411–5. Research Support, N.I.H., Extramural. [PMC free article] [PubMed]
57. Hladik F, Dezzutti CS. Can a topical microbicide prevent rectal HIV transmission? PLoS Med. 2008 Aug 5;5(8):e167. Comment Research Support, N.I.H., Extramural. [PMC free article] [PubMed]
58. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008 Feb;5(2):e28. Comparative Study Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. [PMC free article] [PubMed]
59. McGowan I. Rectal microbicides: can we make them and will people use them? AIDS Behav. 2011 Apr;15(1):S66–71. Research Support, N.I.H., Extramural. [PMC free article] [PubMed]
60. Mowat AM, Viney JL. The anatomical basis of intestinal immunity. Immunol Rev. 1997 Apr;156:145–66. Review. [PubMed]
61. Cerf-Bensussan N, Guy-Grand D. Intestinal intraepithelial lymphocytes. Gastroentero Clin North Am. 1991 Sep;20(3):549–76. Review. [PubMed]
62. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. NatRevMicrobiol. 2003;1(1):25–34. doi: 10.1038/nrmicro729. [PubMed] [Cross Ref]
63. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science. 1998 Apr 17;280(5362):427–31. Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. [PubMed]
64. Ribeiro Dos Santos P, Rancez M, Pretet JL, Michel-Salzat A, Messent V, Bogdanova A, et al. Rapid dissemination of SIV follows multisite entry after rectal inoculation. PLoS One. 2011;6(5):e19493. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. [PMC free article] [PubMed]
65. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 2008 Aug 5;5(8):e157. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. discussion e. [PMC free article] [PubMed]
66. Fuchs EJ, Lee LA, Torbenson MS, Parsons TL, Bakshi RP, Guidos AM, et al. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. The Journal of infectious diseases. 2007 Mar 1;195(5):703–10. Randomized Controlled Trial Research Support, N.I.H., Extramural. [PubMed]
67. Singer R, Derby N, Rodriguez A, Kizima L, Kenney J, Aravantinou M, et al. The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. Journal of Virology. 2011 Jun;85(11):5504–12. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. [PMC free article] [PubMed]
68. Patterson BK, Landay A, Siegel JN, Flener Z, Pessis D, Chaviano A, et al. Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol. 2002 Sep;161(3):867–73. Research Support, U.S. Gov't, P.H.S. [PubMed]
69. Ganor Y, Bomsel M. HIV-1 transmission in the male genital tract. Am J Reprod Immunol. 2011 Mar;65(3):284–91. Review. [PubMed]
70. Donoval BA, Landay AL, Moses S, Agot K, Ndinya-Achola JO, Nyagaya EA, et al. HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol. 2006 Mar;125(3):386–91. Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. [PubMed]
71. McCoombe SG, Short RV. Potential HIV-1 target cells in the human penis. Aids. 2006 Jul 13;20(11):1491–5. [PubMed]
72. Szabo R, Short RV. How does male circumcision protect against HIV infection? Bmj. 2000 Jun 10;320(7249):1592–4. Review. [PMC free article] [PubMed]
73. Kigozi G, Wawer M, Ssettuba A, Kagaayi J, Nalugoda F, Watya S, et al. Foreskin surface area and HIV acquisition in Rakai, Uganda (size matters) Aids. 2009 Oct 23;23(16):2209–13. Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. [PMC free article] [PubMed]
74. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005 Nov;2(11):e298. Randomized Controlled Trial Research Support, Non-U.S. Gov't. [PMC free article] [PubMed]
75. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007 Feb 24;369(9562):643–56. Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. [PubMed]
76. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007 Feb 24;369(9562):657–66. Randomized Controlled Trial. [PubMed]
77. Edwards S, Carne C. Oral sex and the transmission of viral STIs. Sex Transm Infect. 1998 Feb;74(1):6–10. Review. [PMC free article] [PubMed]
78. Coovadia HM, Coutsoudis A. HIV, infant feeding, and survival: old wine in new bottles, but brimming with promise. Aids. 2007 Sep 12;21(14):1837–40. Review. [PubMed]
79. Malamud D, Wahl SM. The mouth: a gateway or a trap for HIV? Aids. 2010 Jan 2;24(1):5–16. Editorial Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Review. [PMC free article] [PubMed]
80. Shugars DC, Wahl SM. The role of the oral environment in HIV-1 transmission. Journal of the American Dental Association. 1998;129(7):851–8. [PubMed]
81. Drannik AG, Henrick BM, Rosenthal KL. War and peace between WAP and HIV: role of SLPI, trappin-2, elafin and ps20 in susceptibility to HIV infection. Biochemical Society transactions. 2011 Oct 1;39(5):1427–32. [PubMed]
82. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, et al. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med. 2004 Nov 15;200(10):1337–46. [PMC free article] [PubMed]
83. Shugars DC. Endogenous mucosal antiviral factors of the oral cavity. Journal of Infectious Diseases. 1999;179(3):S431–5. [PubMed]
84. Kazmi SH, Naglik JR, Sweet SP, Evans RW, O'Shea S, Banatvala JE, et al. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol. 2006 Oct;13(10):1111–8. [PMC free article] [PubMed]
85. Herzberg MC, Vacharaksa A, Gebhard KH, Giacaman RA, Ross KF. Plausibility of HIV-1 Infection of Oral Mucosal Epithelial Cells. Advances in dental research. 2011 Apr;23(1):38–44. Research Support, N.I.H., Extramural Review. [PMC free article] [PubMed]
86. Diamond G, Beckloff N, Weinberg A, Kisich KO. The roles of antimicrobial peptides in innate host defense. Curr Pharm Des. 2009;15(21):2377–92. [PMC free article] [PubMed]
87. Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. Aids. 2003 Nov 7;17(16):F39–48. [PubMed]
88. Sun L, Finnegan CM, Kish-Catalone T, Blumenthal R, Garzino-Demo P, La Terra Maggiore GM, et al. Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol. 2005 Nov;79(22):14318–29. [PMC free article] [PubMed]
89. Tugizov SM, Herrera R, Veluppillai P, Greenspan D, Soros V, Greene WC, et al. HIV is inactivated after transepithelial migration via adult oral epithelial cells but not fetal epithelial cells. Virology. 2011 Jan 20;409(2):211–22. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. [PMC free article] [PubMed]
90. Liu L, Wang L, Jia HP, Zhao C, Heng HHQ, Schutte BC, et al. Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of inflammation. Gene. 1998;222(2):237–44. [PubMed]
91. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. [see comments.] New England Journal of Medicine. 2002;347(15):1151–60. [PubMed]
92. Dale BA, Kimball JR, Krisanaprakornkit S, Roberts F, Robinovitch M, O'Neal R, et al. Localized antimicrobial peptide expression in human gingiva. J Periodontal Res. 2001;36(5):285–94. [PubMed]
93. Gupta S, Ghosh SK, Scott ME, Bainbridge B, Jiang B, Lamont RJ, et al. Fusobacterium nucleatum-associated beta-defensin inducer (FAD-I): identification, isolation, and functional evaluation. The Journal of biological chemistry. 2010 Nov 19;285(47):36523–31. Research Support, N.I.H., Extramural. [PubMed]